May 24, 2024: Dr. Krishna Ella, Co-founder and Executive Chairman of Bharat Biotech, has been awarded the prestigious Dean’s medal by the Johns Hopkins Bloomberg School of Public Health. The award was presented to Dr. Ella during Bloomberg School’s Convocation Ceremony on May 22nd, 2024, in Baltimore, Maryland, for his exceptional leadership, enduring vision and contribution to improving public health.
John Hopkins Bloomberg School of Public Health acknowledges Dr. Krishna Ella’s pioneering work, remarkable influence, and determination to develop an indigenous, innovative, and safe vaccines focused on global public health.
On receiving the Dean’s Medal from Johns Hopkins Bloomberg School of Public Health Dr. Krishna Ella said, “I acknowledge this medal as a global recognition of India’s scientific excellence, and dedicate this medal to Bharat, which has shown remarkable success by advancing science and R&D, to our exemplary team of scientists, and the results of our strong commitment to public.”
Under Dr. Ella’s guidance, Bharat Biotech emerged as a leader in global biotechnology and vaccine innovation, with innovative vaccines, manufactured at large scale, and affordable costs. With a portfolio of over 19 vaccines, including the world’s first typhoid conjugate vaccine, Typbar TCV®, rotavirus vaccine, ROTAVAC®, and Japanese Encephalitis Vaccine, JENVAC®. Bharat Biotech has played a critical role in addressing public health challenges in India and worldwide. With supplies of more than 9 billion doses till date, Bharat Biotech has saved millions of lives and improved livelihoods for millions globally.
During the COVID-19 pandemic, Bharat Biotech developed COVAXIN®, India’s first Indigenous COVID-19 vaccine in a record time, conducting the largest-ever human clinical trials and peer-reviewed by world-leading medical journals. COVAXIN® has been instrumental in the country’s vision of self-reliance, in the fight against the virus, demonstrating significant efficacy and safety. The vaccine has been distributed globally, reinforcing Dr. Ella’s commitment to advancing healthcare accessibility and innovation worldwide. He now serves as the President of the Indian Vaccine Manufacturers’ Association (IVMA).
Dr. Krishna Ella, father of Genome Valley receives highest medal of honor for improving global public health
Under Dr. Ella’s leadership, Bharat Biotech is developing promising vaccines against Cholera, Malaria, Tuberculosis, Chikungunya, Zika, S. ParatyphiA, S. Typhimurium, S. Enteritidis, etc., which are in crucial clinical trial phases.
Dr. Krishna Ella is a first-generation entrepreneur, who established Bharat Biotech in the year 1996 is widely acknowledged for not only leading his company to a leadership position in paediatric and adult vaccine development, but also establishing world-class enterprises focused on human health, animal health (Biovet India), food processing (Ella Foods), and contract research services.
Led by Dr. Ella, Bharat Biotech has emerged as a global leader with 145 patents, ~20 vaccines, and bio-therapeutics, delivering more than 9 billion doses of lifesaving vaccines across 125 nations. Dr. Ella has made exceptional contributions to global health security by developing vaccines, focusing on finding affordable vaccines to fight neglected diseases that impact developing nations, backed by a safety-first approach.
Dr. Krishna Ella is acknowledged as the father of Genome Valley in Hyderabad, for his significant contributions in developing the vaccine ecosystem. which is now the largest cluster of life sciences in India. An ardent proponent of start-ups and innovation, he inspires the scientific world through his tireless dedication to making India a global powerhouse in vaccine research and development. He is further encouraging public and private sector collaboration.
